Star Equity Competitors

Medtronic (NYSE:MDT) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Medtronic and Star Equity's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Medtronic and Star Equity, as provided by MarketBeat.com.

Medtronic currently has a consensus target price of $124.2692, indicating a potential upside of 0.30%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Star Equity.

Valuation & Earnings

This table compares Medtronic and Star Equity's top-line revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Star Equity.

Risk & Volatility

Medtronic has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Institutional and Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 12.5% of Star Equity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats Star Equity on 12 of the 13 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Risk & Volatility

Varian Medical Systems has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Valuation and Earnings

This table compares Varian Medical Systems and Star Equity's revenue, earnings per share and valuation.

Varian Medical Systems has higher revenue and earnings than Star Equity.

Institutional & Insider Ownership

87.0% of Varian Medical Systems shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 0.8% of Varian Medical Systems shares are owned by insiders. Comparatively, 12.5% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Varian Medical Systems and Star Equity's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Varian Medical Systems and Star Equity, as reported by MarketBeat.

Varian Medical Systems presently has a consensus target price of $159.3571, indicating a potential downside of 10.00%. Given Varian Medical Systems' higher probable upside, equities research analysts clearly believe Varian Medical Systems is more favorable than Star Equity.

Summary

Varian Medical Systems beats Star Equity on 10 of the 11 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 11.5% of Masimo shares are owned by insiders. Comparatively, 12.5% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Masimo and Star Equity, as provided by MarketBeat.

Masimo currently has a consensus price target of $272.20, indicating a potential upside of 13.63%. Given Masimo's higher possible upside, research analysts clearly believe Masimo is more favorable than Star Equity.

Earnings & Valuation

This table compares Masimo and Star Equity's top-line revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than Star Equity.

Profitability

This table compares Masimo and Star Equity's net margins, return on equity and return on assets.

Summary

Masimo beats Star Equity on 11 of the 12 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Volatility and Risk

LivaNova has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. Comparatively, 10.1% of Star Equity shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Comparatively, 12.5% of Star Equity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for LivaNova and Star Equity, as reported by MarketBeat.

LivaNova presently has a consensus target price of $69.3333, suggesting a potential downside of 14.79%. Given LivaNova's higher probable upside, equities research analysts plainly believe LivaNova is more favorable than Star Equity.

Profitability

This table compares LivaNova and Star Equity's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares LivaNova and Star Equity's gross revenue, earnings per share and valuation.

Star Equity has lower revenue, but higher earnings than LivaNova.

Summary

LivaNova beats Star Equity on 8 of the 12 factors compared between the two stocks.

Star Equity (NASDAQ:STRR) and CONMED (NYSE:CNMD) are both multi-sector conglomerates companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Profitability

This table compares Star Equity and CONMED's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Star Equity and CONMED, as provided by MarketBeat.

CONMED has a consensus target price of $104.60, suggesting a potential downside of 19.82%. Given CONMED's higher probable upside, analysts clearly believe CONMED is more favorable than Star Equity.

Insider & Institutional Ownership

10.1% of Star Equity shares are owned by institutional investors. 12.5% of Star Equity shares are owned by company insiders. Comparatively, 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Earnings & Valuation

This table compares Star Equity and CONMED's top-line revenue, earnings per share (EPS) and valuation.

CONMED has higher revenue and earnings than Star Equity.

Summary

CONMED beats Star Equity on 9 of the 12 factors compared between the two stocks.

InMode (NASDAQ:INMD) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 12.5% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for InMode and Star Equity, as provided by MarketBeat.com.

InMode presently has a consensus price target of $71.50, indicating a potential downside of 14.40%. Given InMode's higher possible upside, analysts clearly believe InMode is more favorable than Star Equity.

Valuation and Earnings

This table compares InMode and Star Equity's revenue, earnings per share and valuation.

InMode has higher revenue and earnings than Star Equity.

Profitability

This table compares InMode and Star Equity's net margins, return on equity and return on assets.

Risk and Volatility

InMode has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Summary

InMode beats Star Equity on 11 of the 12 factors compared between the two stocks.